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Atrial fibrillation (AF) is the commonest sustained arrhythmia globally and results in significantly increased morbidity and
mortality including a fivefold risk of stroke. Paroxysmal atrial fibrillation (PAF) constitutes approximately half of all AF cases
and is thought to represent an early stage of the disease. This intermittent form of atrial arrhythmia can be a challenge to identify
and as a result many affected individuals are not prescribed appropriate antithrombotic therapy and hence are at risk of stroke
and thromboembolism. Despite these adverse outcomes there have been relatively few diagnostic advances in the field since the
introduction of the Holter monitor in 1949.This review aims to establish the available evidence for electrophysiological, molecular,
and morphological biomarkers to improve the detection of PAF with reference to the underlying mechanisms for the condition.
1. Introduction
Atrial fibrillation (AF) is the most frequently encountered
cardiac arrhythmia globally, affecting 2% of the general
population and rising to 10% of those aged over 80 years.
One in four individuals will experience AF in their lifetime
[1]. By 2050 the prevalence of AF is expected to increase by
threefold and this poses a considerable public health concern
[2]. Overall AF exacerbates the risk of stroke and is associated
with a twofold excess mortality with 20% of all strokes being
as a result of AF and 1 in 5 patients first presenting with
AF in the context of cerebral ischaemia [3]. In addition AF
is also linked to larger strokes based on both clinical and
radiological findings [4]. Despite these risks, it has been
estimated that at least 20%of cases of AF remain undiagnosed
and are not prescribed appropriate stroke prevention therapy
[5].
Paroxysmal atrial fibrillation (PAF) is thought to consti-
tute between 25 and 60% of cases of AF [6] and is thought
to precede sustained AF, culminating in progressive atrial
electrical and structural remodelling, otherwise coined “AF
begets AF.” PAF has been defined by the American Heart
Association as “recurrent (two or more) episodes of AF that
terminate spontaneously lasting between 30 seconds and less
than seven days” [7]. An example of the initiation of PAF is
seen in Figure 1.
The true prevalence of PAF is unknown due to asymp-
tomatic episodes and a low yield afforded by conventional
monitoring. However between 6 and 28% of cryptogenic
strokes have been found to be secondary to PAF [8] and
PAF conveys an equivalent risk of stroke to sustained forms
of AF [9]. Unfortunately PAF, relative to the other forms of
AF termed “persistent” and “permanent,” can be a particular
challenge to diagnose due to the variable onset of the arrhyth-
mia, potential brevity, and also frequent lack of symptoms
[10].
2. Pathophysiology of Atrial Fibrillation
The cardiac action potential (AP) is a key determinant
of cardiac electrical activity and results from transmem-
brane ion fluxes through ion channels and transporters. A
schematic representation of a human atrial action potential
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Figure 1: An ECG recording from a continuous cardiac monitor
from a patient suffering from paroxysmal atrial fibrillation (PAF)
lasting for several hours. The arrow marks the onset of AF, charac-
terised by a variable R-R interval (representing the time between two
successive ventricular contractions) and loss of P-waves (absence of
coordinated atrial activity) (unpublished).
and the principal currents involved is shown in Figure 2(a).
The resting potential is maintained at about −80mV via K+
equilibrium potential. Upon activation, rapid depolarization
occurs by a large inward Na+ current (𝐼Na) and an inward
Ca2+ current via L-type Ca2+ channels (𝐼CaL) resulting in the
plateau phase. As theCa2+ current declines theAP repolarizes
to the resting potential.
Arrhythmia generation in the left atrium (LA) originates
from a combination of abnormalities in impulse initiation,
impulse conduction, or a combination of the two [11]. Abnor-
mal impulse initiation can be subclassified further due to
enhanced automaticity or triggered activity. Enhanced auto-
maticity (ectopic arrhythmias) may be produced by irreg-
ular intracellular Ca2+ release. Similarly triggered activity,
caused by a spontaneous inward current, generates secondary
afterdepolarizations early in the plateau phase (EADs) or
upon repolarisation (DADs) (Figure 2(b)). Alternatively due
to abnormal AP conduction, reentrant arrhythmias occur,
preventing the normal pattern of propagation across the
myocardium. This is attributable to a combination of alter-
ation of the electrical properties of intercellular gap junctions;
structural remodelling of the myocardium; and generation of
EADs/DADs that per se have slower conduction. Both mech-
anisms may be present simultaneously where ectopic activity
begets reentrant arrhythmias resulting in self-perpetuation.
The former described electrophysiological mechanisms
are coupled to atrial electrical remodeling, characterised
by changes in atrial refractoriness and slowed conduction
time. These changes occur due to alterations in AP currents,
especially Ca2+ influx and its subsequent homeostasis, and
provide ongoing atrial arrhythmogenic substrates [12].
Atrial structural remodeling is typified by cardiac fibro-
sis, characterized by accumulation of collagenous material
in the extracellular space (Figure 3), and is proposed to
widen gap junctions and decrease communication between
cardiomyocytes. Reduced AP conduction velocity is directly
correlated to the extent of fibrosis and is linked to persistent
reentrant circuit arrhythmias [13]. Angiotensin II produced
by fibroblasts exacerbates the situation to increase cellular
proliferation and cardiac fibrosis [14]. Alternatively structural
remodeling may arise due to the release of proinflammatory
cytokines after surgery or injury and the interaction of
inflammatory proteins with angiotensin II promotes further
atrial fibrosis [15]. This inflammatory response has been
implicated in the aetiology of AF although the question
remains whether this is attributable to the arrhythmia itself
or another underlying disease state [16].
The ultimate consequences of AF, stroke and systemic
embolism, result from the dislodgement of LA thrombi.
Thrombus is most commonly located in the left atrial
appendage (LAA) [17], a small pouch found in the LA
(Figure 4). The generation of thrombi is triggered by atrial
stasis, as a result of impaired atrial contraction due to atrial
arrhythmia. Other factors promoting thrombus formation
include damage to the atrial wall and a hypercoagulable state
[18].
3. Current Diagnostics for Paroxysmal
Atrial Fibrillation
Current methods to diagnose PAF are limited to electro-
cardiogram (ECG) analysis, which may fail to document
an episode of AF if occurring outside the monitoring
period. Recent trials have highlighted that prolonged cardiac
monitoring detects significantly more cases of PAF in the
cryptogenic stroke population than using a conventional 24-
hour Holter monitor [19, 20]. Clinical risk factors for AF are
widely recognized andmodels have been proposed to predict
incident AF using a number of clinical variables. Such a risk
score devised by the Framingham Heart Study is based on a
number of simple clinical parameters including age, gender,
a significant murmur, cardiac failure, systolic blood pressure,
hypertension, body mass index, and PR interval. The score
yielded a C-statistic of 0.78 (95% CI 0.76–0.80), with a C-
statistic being a measure of a model’s predictive power and
a value of over 0.7 considered to be reasonable. The addition
of echocardiographicmeasurements further improved this to
0.79 [21]. There is however a lack of diagnostic armoury to
detect PAF. This is in stark contrast to other cardiovascular
conditions, for example, coronary artery disease and cardiac
failure, with a comparable disease prevalence and routine use
of diagnostic biomarkers [22].
4. Biomarkers
A biomarker can be defined as “a characteristic that is
objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention” [23]. Biomarkers
not only have the potential to identify a disease process but
also provide valuable information about underlying disease
mechanisms and, as a consequence, potential therapeutic
targets.
Biomarkers have been proposed as a tool to predict
onset of AF in a variety of settings including at initial pre-
sentation, following cardiothoracic surgery, recurrence after
cardioversion and ablation, and in the event of a cryptogenic
stroke. Additionally, accumulating research has shown that
biomarkers could be used to predict the transition of PAF to
sustained AF, as well as, alongside conventional risk scores,
to determine thromboembolic risk [24, 25]. The LA has been
the main focus for identifying biomarkers for PAF given the
inextricable association between this chamber and the disease
process itself. As such potential biomarkers to detect PAF can
be broadly categorised into electrophysiological, molecular,
and morphological indices.
BioMed Research International 3
250ms
−70mV
30mV
IK1
INa
Ito
IKATP
IKur
IKs
IKr
ICaL
(a)
EAD
RyR dysfunction
NCX activation
DAD
IK1
INa
Ito
IKATP
IKur
IK5
IKr
ICaL
Increased persistent INa
Loss of IK function
Slowed 
down
repolarization
(ICaL reactivation)
(b)
Figure 2: Illustrative diagram of a typical human left atrial AP with associated currents shown above (a). Electrical remodeling can result
in abnormal APs (b). 𝐼CaL reactivation (blue) can cause early-after depolarization (EAD) that may result in repetitive EAD. Alternatively
spontaneous ryanodine receptor (RYR) release or Na+/Ca2+ exchanger activation (NCX) (red) would result in delayed-after depolarization
(DAD) (unpublished).
(a) (b)
Figure 3: Staining of the left atrial appendage demonstrating fibrosis stained with vimentin (green) in a patient in sinus rhythm (a) and AF
(b) (unpublished).
5. Biomarkers for Paroxysmal
Atrial Fibrillation
5.1. Electrophysiological Biomarkers. A number of studies
have shown that simple resting ECG parameters are highly
predictive of PAF. “P-maximum” is the maximum duration
from the onset to the end of the P-wave deflection from all
12 ECG leads. This is seen as a marker of prolonged atrial
conduction time, a hallmark of patients with AF. “P wave dis-
persion,” the difference between themaximumandminimum
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Figure 4:Thrombus visualized in the left atrial appendage ismarked
with an arrow (unpublished).
P-wave duration in any of the 12 leads, signifies nonuniform
atrial conductivity. Both parameters are representative of the
underlying atrial remodelling occurring inAF and previously
alluded to. One study showed that P-maximum and P-wave
dispersionwere highly predictive of previous episodes of PAF.
A P-maximum of at least 110ms had a sensitivity of 88%
and specificity of 75% and a P-wave dispersion of at least
40ms yielded a sensitivity of 83% and specificity of 85% for
PAF [26]. These findings have been substantiated by another
study showing that P-wave dispersion was an independent
predictor of PAF in stroke patients. In this population a P-
wave dispersion 57.5ms and above predicted PAF with a
sensitivity and specificity of 80% and 73%, respectively [27].
Likewise a J-shaped relationship was shown between the
QTc interval and risk of incident AF in a large primary
care population. QTc intervals at the 99th percentile and
above (≥464ms) resulted in an overall hazard ratio of 1.44
for all AF subtypes. Additionally an even more powerful
relationship was seen in lone AF with a QTc interval ≥458ms
demonstrating a hazard ratio of 2.32. Conversely a QTc
≤372ms was associated with a hazard ratio of 1.45 [28].
More specific to PAF, another group have shown that a
prolonged QTc interval is an independent predictor of PAF
in patients presenting with ischaemic stroke. In this instance
a QTc threshold ≥438ms generated a sensitivity of 59.4%
and specificity of 83.7% [29]. It has been proposed that these
associationsmay be on account of universal expression of ion
channels in both atrial and ventricular tissue.
Atrial premature beats (APBs) precede PAF in a signifi-
cant proportion of AF episodes and are a feature of enhanced
automaticity, a recognised mechanism for AF (Figure 5). In
one study monitoring 33 patients with documented PAF and
297 total episodes of AF, the arrhythmia was initiated by
APBs in 93% of cases [30]. Consequently frequent APBs
have been suggested as a marker of predisposition to PAF.
One study investigating 98 stroke patients with transtele-
phonic monitoring determined that at least 100 APBs on
a 24-hour Holter monitor equated to an odds ratio of 11 for
the subsequent development of PAF after one month [31].
Ectopic beat
1mV
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Figure 5: An example of an atrial premature beat is marked
(unpublished).
In another cohort of stroke patients, greater than 4 APBs
per hour during an initial 24-hour Holter monitor equated to
subsequent development of PAF in 19.6%, compared to 2.8%
in those with 4 APBs per hour or less [32]. Using a similar
study design, Wallmann et al. also deduced that frequent
APBs were an independent risk factor for PAF in stroke
patients. Significantly more of those patients with frequent
APBs (defined as at least 70 in 24 hours) developed PAF at
22.4months comparedwith thosewith infrequentAPBs (33%
versus 5%) [33].
5.2. Molecular Biomarkers. Previously validated biomarkers,
currently used in standard clinical practice to diagnose car-
diac failure and myocardial infarction, have also been tested
in the setting of AF. Numerous studies have shown an associ-
ation between AF and brain natriuretic peptide (BNP) with
persistently higher plasma levels than in healthy matched
controls and a reduction to that of control subjects following
successful restoration of sinus rhythm [34]. It has been
proposed that the main source of BNP release in AF is the
atrium as a result of pressure and volume overload. It remains
to be established however whether BNP is merely a marker
of atrial dysfunction or active in the underlying pathological
process [35]. With a particular focus on PAF, several studies
have shown a relationship between natriuretic peptides and
diagnosis of this arrhythmia. One study showed higher levels
of plasma BNP in patients with lone PAF compared to age-
and sex-matched controls [36]. A further study confirmed
significantly raised N-terminal of prohormone brain natri-
uretic peptide (NT-proBNP, a peptide cleaved from pro-
BNP to release BNP) in contrast to matched controls. Yet
a similar relationship was not demonstrated for pro-ANP
(atrial natriuretic peptide) in this group [37]. Likewise in the
Find-AF study, BNP levels were significantly higher in those
cryptogenic stroke patients with confirmed PAF than those
without [38]. A similar prospective study found that a BNP
over 140 pg/mL had a sensitivity and specificity of 77.6% and
84.8%, respectively, for cardioembolic stroke [39]. Likewise
NT-proBNP levels over 265.5 pg/mL conferred a sensitivity
100% and specificity 70.5% for PAF [40]. Similarly troponin,
another established cardiac biomarker, is increased in PAF
subjects relative to their controls. Elevation of troponin levels
in cryptogenic stroke patients independently predicted new
onset AF during 24-hourHoltermonitoring [41].This finding
was also confirmed in a similar retrospective study [42].
Markers of inflammation, implicated in the pathogenesis
of AF, have yielded mixed results. Raised serum IL-18 was
significantly associated with both PAF and persistent AF
with a twofold concentration in all AF subtypes compared
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to controls [43]. Another study confirmed that patients
with PAF had significantly higher levels of CRP (C-reactive
protein) than their controls, in a graded fashion according
to arrhythmia burden [44]. Similarly a raised white blood
cell count predisposed to incident AF after 5 years in the
Framingham Study [45]. In stark contrast another study
demonstrated no difference in the inflammatory markers
CRP, IL-6, and IL-8 between PAF patients and their controls
when attending for radiofrequency ablation [46]. Glucose
haemostasis and lipid metabolism also appear to be associ-
ated with the development of AF. In the Atherosclerosis Risk
in Communities (ARIC) cohort a positive linear relationship
was seen between haemoglobin A1c (HbA1c) and incident
AF in patients both with and without type 2 diabetes
[47]. Interestingly in the Women’s Health Study however,
although HbA1c was positively correlated with the incidence
of nonparoxysmal AF, it was inversely related to PAF [48].
Additionally the ARIC study demonstrated that both higher
LDL and total cholesterol resulted in a lower incidence of
all AF subtypes [49]. This, somewhat unexpected, inverse
relationship was replicated by another group [50] yet an
explanation for this repeated finding is not clear.
Parameters reflecting thrombogenesis, the source of car-
dioembolism and stroke in PAF, have also been investigated.
For example, plasma von Willebrand factor and fibrinogen
were significantly elevated in patients with PAF compared to
their matched controls [51]. Similarly fibrinogen and fibrin
D-dimer were significantly increased in PAF relative to age-
and sex-matched controls [52]. Additionally regulators of
extracellular turnover, the culprits of the previously described
fibrotic remodelling, were all increased in lone PAF sub-
jects compared to their controls. These markers include
CICP (C-terminal propeptide of collagen type-I), CITP (C-
terminal telopeptide of collagen type-I), MMP-1 (matrix
metalloproteinase-1), and TIMP-1 (tissue inhibitor of matrix
metalloproteinase) [53]. Likewise CITP was also raised in
PAF cases compared to healthy subjects in another study [54].
Both of these studies were limited by a younger control group
however, introducing potential confounding.
A genetic predisposition has been shown to contribute
to the development of AF. For example, the Framingham
Study showed a heightened risk of AF in the children of
a parent with AF, independent of other risk factors (odds
ratio of 1.85) [55]. Genetic analysis of over 14,000 European
and Japanese individuals with a history of AF noted suscep-
tibility signals on chromosome 4q25, upstream of PTIX2,
a gene previously implicated in AF [56]. Furthermore six
further susceptibility loci (1q24, 7q31, 14q23, 9q22, 15q24, and
10q22) were identified in a meta-analysis comprising over
10,000 individuals with AF of European decent [57]. These
findings prompted the Women’s Health Study to validate
a prediction score for incident AF incorporating 12 single-
nucleotide polymorphisms in nine loci. Genetic risk markers
were shown to improve a conventional clinical risk score
from a C-statistic of 0.718 to 0.741 (𝑃 = 0.001) [58].
Whether genetic markers will aid in the diagnosis of PAF
in particular is, as yet, to be definitively answered. There
is however promising research suggesting that microRNAs,
stable noncoding RNAs (ribonucleic acid) found in serum
and plasma which modulate RNA transcription, may play
such a role. There is a relative paucity of research in this
area to date and studies investigating a link to PAF are even
scarcer. However promisingly, several preliminary studies
have shown that plasma miRNA-150 expression, already
implicated in the regulation of genes associated with atrial
remodeling, is significantly reduced in individuals with PAF
[59, 60].
5.3. Morphological Biomarkers. It is widely recognised that
LA size is a powerful predictor of cardiovascular mortality,
conferring an independent 2.3-fold excess risk of cardio-
vascular mortality at 13 years [61]. Specific to AF, each
increase in LA diameter by 5mm increased the risk of new
AF by 39% in the Framingham Heart Study [62]. Likewise
subjects with PAF had increased LA size relative to healthy
controls with an inferosuperior dimension of at least 50mm,
yielding a sensitivity and specificity for PAF of 66% and 80%,
respectively [63]. These observations are a direct result of the
structural remodelling occurring in the LA in the course of
the disease process.
With the advent of increasingly sophisticated techniques
to assess the LA, echocardiographic indices of function
are now widely thought to be more robust predictors of
outcomes than size alone [64, 65]. Methods to assess LA
function include Doppler analysis of transmitral flow and
tissue Doppler assessment of LA myocardial velocities. Not
only have alterations in LA function been shown to be a
hallmark for PAF, but also they may predict the onset of AF
following cardiothoracic surgery, cardioversion, and ablation,
as well as being an independent marker of thromboembolic
risk [66–69]. Variables of LA function, as assessed using
transoesophageal echocardiography (TOE), were impaired
in PAF patients following stroke. LAA peak velocity was
markedly reduced in the PAF group compared to the control
group. Additionally LA spontaneous echo contrast, graded
from 0 (none) to 4+ (severe), was higher in the PAF group.
Both of these measurements reflect atrial stasis and were
more powerful predictors of PAF than LA dimension alone
[70].
These results have been replicated using transthoracic
echocardiography where, LA function as assessed bymyocar-
dial Doppler, is thought to predict PAF more precisely than
LA dimensions. Toh et al. used a novelmarker of both LA size
combined with LA pump function [LAVI/a󸀠] to discriminate
between patients with PAF in a group of hypertensive
patients. LAVI (left atrial volume index) is calculated from
the LA volume corrected for body surface area. Left atrial
velocity in late diastole, or a󸀠, is derived from myocardial
tissue Doppler measured from the mitral annulus (Figure 6).
In this population a LAVI/a󸀠 threshold of 2.7 conferred a
sensitivity 82% and specificity 91% for PAF. [71].The Find-AF
group used the same method to distinguish between stroke
or TIA patients with underlying PAF. It was deduced that
LAVI/a󸀠 of 2.3 had a 93% sensitivity and 55.8% specificity.
Again this parameter predicted PAF more powerfully than
measures of LA size, including LA diameter and LAVI [72].
Mitral valve disease is commonly associated with a
concurrent diagnosis AF, attributed to atrial remodeling and
6 BioMed Research International
Left atrium
Lateral
mitral
annulus
(a)
a󳰀
(b)
Figure 6: Measurement of left atrial velocity using tissue Doppler. The left image demonstrates the position of the probe at the lateral mitral
annulus. The right image represents the velocities generated during diastole with the atrial component (termed a󸀠) marked (unpublished).
dilatation as a result of volume and pressure overload. For
example, over 40% of individuals with rheumaticmitral valve
disease and between 44 and 48% of those with degenerative
mitral regurgitation (MR) develop AF in the long-term
[73, 74]. One observational study has proposed a form of
“functional MR” as a direct consequent of AF, possibly
induced by atrial wall dyssynchrony, which improves follow-
ing restoration of sinus rhythm [75]. As a predictive tool, one
group proposed that, in patients with at least moderate MR,
the rate of left ventricular pressure rise in early systole (dP/dt
max) independently predicted new onset AF or ischaemic
stroke. The study was significantly limited by a small sample
size with only 9 patients having this combined end point [76].
To our knowledge no large studies assessing the use ofMRas a
diagnostic marker for PAF specifically have been undertaken
to date.
6. Conclusions
Despite several decades of plausible research suggesting that
biomarkers might be used to improve the diagnosis of PAF
(summarised in Table 1) these techniques have not as yet
entered clinic practice.This begs the question why this might
be the case.
There appears to have been a shift in clinicians’ and
scientists’ attitudes to AF in recent years and PAF is no
longer seen as a benign entity. This and the impending
“AF epidemic” have highlighted the importance of optimal
arrhythmia detection. This had been somewhat neglected
previously with the 24-hour Holter monitor remaining com-
monplace as a first-line investigation. Critically the lack of a
universal definition for PAFhas hindered research in the field.
AF research is riddled with conflicting definitions primarily
dependent on the duration of the arrhythmia and tendency
to self-terminate. Furthermore a lack of consensus may be
due to oversimplified classification systems. AF is a hetero-
geneous condition likely to represent a number of underlying
pathologies and a lack of aetiological classification may have
hindered the quest for improved diagnostic markers.
The majority of the literature in this review suggests that
biomarkers might be a valuable addition to current investi-
gational techniques. However these findings are admittedly
subject to inherent publication bias. Furthermore recurrent
methodological flaws are encountered. Many of the papers
published in the area consist of small populations. Addition-
ally a number of groups relied on self-reportedAF as opposed
to objective screening. Crucially many of the control groups
were younger than those with confirmed PAF. Given that
age is an independent risk factor for AF and with age comes
increasing comorbidity, this introduces confounding. Lastly a
number of the techniques described are time-consuming and
some echocardiographic techniques are hindered by difficult
patient anatomy.
In summary it remains an open question if biomarkers
will add to conventional diagnostic techniques for PAF.
If the role of biomarkers is to be established then future
research requires refinement. We propose that an accurate
future biomarker is likely to feature a combination of electro-
physiological, molecular, and morphological indices there-
fore encompassing the heterogeneity seen in this condition.
A reliable diagnostic marker to improve the diagnosis of
undetected PAF and ultimately reduce risk of consequent
thromboembolism certainly warrants further investigation.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The authors would like to thank the Heart and Stroke Trust
Endeavour (HASTE) for supporting their work.They are also
grateful to Dr. Krystyna Darasz for supplying Figure 4.
BioMed Research International 7
Ta
bl
e
1:
A
su
m
m
ar
y
of
th
em
ai
n
ad
va
nt
ag
es
an
d
di
sa
dv
an
ta
ge
so
fc
ur
re
nt
di
ag
no
st
ic
te
ch
ni
qu
es
fo
rP
A
F
(n
ot
bo
ld
)i
nc
lu
di
ng
po
te
nt
ia
lb
io
m
ar
ke
rs
fo
rP
A
F
ba
se
d
on
th
ee
vi
de
nc
ed
et
ai
le
d
in
th
is
re
vi
ew
(b
ol
d)
(u
np
ub
lis
he
d)
.
D
ia
gn
os
tic
cla
ss
Te
ch
ni
qu
e
Se
ns
iti
vi
ty
Sp
ec
ifi
ci
ty
Au
to
m
at
ed
an
al
ys
is
Re
m
ot
e
an
al
ys
is
C
os
t
Ad
va
nt
ag
es
D
isa
dv
an
ta
ge
s
EC
G
rh
yt
hm
m
on
ito
rin
g
C
on
tin
uo
us
lo
ng
-te
rm
EC
G
m
on
ito
rin
g
us
in
g
im
pl
an
ta
bl
ed
ev
ic
es
H
ig
h
H
ig
h
+
+
H
ig
h
H
ig
h
se
ns
iti
vi
ty
an
d
sp
ec
ifi
ci
ty
C
os
tly
,i
nv
as
iv
e
eq
ui
pm
en
tr
eq
ui
re
d
M
ed
iu
m
-te
rm
no
ni
nv
as
iv
e
EC
G
m
on
ito
rin
g
>
24
ho
ur
s
M
od
er
at
e
H
ig
h
+/
−
+/
−
M
od
er
at
e
M
od
er
at
es
en
sit
iv
ity
an
d
sp
ec
ifi
ci
ty
Pa
tie
nt
in
co
nv
en
ie
nc
e,
so
m
e
ca
se
sm
iss
ed
Sh
or
t-t
er
m
EC
G
m
on
ito
rin
g
-2
4
ho
ur
s
Lo
w
H
ig
h
+/
−
+/
−
Lo
w
to
m
od
er
at
e
Re
lat
iv
ely
in
ex
pe
ns
iv
e
Lo
w
di
ag
no
st
ic
yi
el
d
El
ec
tro
ph
ys
io
lo
gi
ca
l
Bi
om
ar
ke
rs
A
na
ly
sis
of
EC
G
in
di
ce
s,
fo
re
xa
m
pl
e,
P
wa
ve
di
sp
er
sio
n,
Q
Tc
in
te
rv
al
Lo
w
to
hi
gh
M
od
er
at
e
to
hi
gh
−
−
Lo
w
C
os
t-e
ffe
ct
iv
et
es
ta
lre
ad
y
in
ro
ut
in
ec
lin
ic
al
pr
ac
tic
e
Re
la
tiv
el
yl
ab
ou
r
in
te
ns
iv
ew
ith
ou
t
au
to
m
at
ed
an
al
ys
is.
Ro
om
fo
rp
ot
en
tia
l
er
ro
r
Fr
eq
ue
nc
yo
fa
tr
ia
l
pr
em
at
ur
eb
ea
ts
on
24
-h
ou
r
H
ol
te
rm
on
ito
r
M
od
er
at
e
Lo
w-
m
od
er
at
e
+/
−
+/
−
Lo
w
to
m
od
er
at
e
N
on
in
va
siv
et
es
tw
hi
ch
th
e
pa
tie
nt
m
ay
al
re
ad
yb
e
un
de
rg
oi
ng
Lo
w
sp
ec
ifi
ci
ty
M
ol
ec
ul
ar
bi
om
ar
ke
rs
Pr
ot
ei
ns
M
od
er
at
et
o
hi
gh
M
od
er
at
e
+
−
Lo
w
M
as
ss
cr
ee
ni
ng
po
ss
ib
le
Re
la
tiv
el
yl
ow
sp
ec
ifi
ci
ty
m
ic
ro
RN
As
Ex
pe
ct
ed
to
be
eq
ui
va
le
nt
to
pr
ot
ei
n
bi
om
ar
ke
rs
M
or
ph
ol
og
ic
al
bi
om
ar
ke
rs
Ec
ho
ca
rd
io
gr
ap
hy
LA
siz
e
Lo
w
M
od
er
at
e
−
−
M
od
er
at
e
N
on
in
va
siv
et
es
tw
hi
ch
th
e
pa
tie
nt
m
ay
al
re
ad
yb
e
un
de
rg
oi
ng
.L
A
siz
ei
sa
st
an
da
rd
m
ea
su
re
m
en
t
H
ig
hl
yt
ra
in
ed
sp
ec
ia
lis
ts
an
d
co
st
ly
eq
ui
pm
en
tr
eq
ui
re
d
Ec
ho
ca
rd
io
gr
ap
hy
LA
fu
nc
tio
n,
fo
r
ex
am
pl
e,
m
yo
ca
rd
ia
l
tis
su
eD
op
pl
er
H
ig
h
M
od
er
at
e
−
−
M
od
er
at
e
N
on
in
va
siv
et
es
tw
hi
ch
th
e
pa
tie
nt
m
ay
al
re
ad
yb
e
un
de
rg
oi
ng
H
ig
hl
yt
ra
in
ed
sp
ec
ia
lis
ts
an
d
co
st
ly
eq
ui
pm
en
tr
eq
ui
re
d.
Po
te
nt
ia
lr
oo
m
fo
r
er
ro
ri
n
pa
tie
nt
sw
ith
su
bo
pt
im
al
im
ag
e
qu
al
ity
8 BioMed Research International
References
[1] D. M. Lloyd-Jones, T. J. Wang, E. P. Leip et al., “Lifetime risk for
development of atrial fibrillation: the framingham heart study,”
Circulation, vol. 110, no. 9, pp. 1042–1046, 2004.
[2] Y. Miyasaka, M. E. Barnes, B. J. Gersh et al., “Secular trends in
incidence of atrial fibrillation in Olmsted County, Minnesota,
1980 to 2000, and implications on the projections for future
prevalence,” Circulation, vol. 114, no. 2, pp. 119–125, 2006.
[3] D. A. Dulli, H. Stanko, and R. L. Levine, “Atrial fibrillation is
associated with severe acute ischemic stroke,” Neuroepidemiol-
ogy, vol. 22, no. 2, pp. 118–123, 2003.
[4] H.-J. Lin, P. A. Wolf, M. Kelly-Hayes et al., “Stroke severity in
atrial fibrillation: the Framingham study,” Stroke, vol. 27, no. 10,
pp. 1760–1764, 1996.
[5] J. L. Clua-Espuny, I. Lechuga-Duran, R. Bosch-Princep et al.,
“Prevalence of undiagnosed atrial fibrillation and of that not
being treated with anticoagulant drugs: the AFABE study,”
Revista Espan˜ola de Cardiologı´a, vol. 66, no. 7, pp. 545–552, 2013.
[6] R. C. S. Seet, P. A. Friedman, and A. A. Rabinstein, “Prolonged
rhythmmonitoring for the detection of occult paroxysmal atrial
fibrillation in ischemic stroke of unknown cause,” Circulation,
vol. 124, no. 4, pp. 477–486, 2011.
[7] V. Fuster, L. E. Ryde´n, D. S. Cannom et al., “ACC/AHA/ESC
2006 Guidelines for the Management of Patients with Atrial
Fibrillation: a report of the American College of Cardiol-
ogy/AmericanHeart Association Task Force on Practice Guide-
lines and the European Society of Cardiology Committee for
Practice Guidelines,” Circulation, vol. 114, no. 7, pp. e257–e354,
2006.
[8] M. Khan and D. J. Miller, “Detection of paroxysmal atrial fib-
rillation in stroke/Tia patients,” Stroke Research and Treatment,
vol. 2013, Article ID 840265, 5 pages, 2013.
[9] R. G. Hart, L. A. Pearce, R. M. Rothbart, J. H. McAnulty, R.
W. Asinger, and J. L. Halperin, “Stroke with intermittent atrial
fibrillation: incidence and predictors during aspirin therapy,”
Journal of the American College of Cardiology, vol. 35, no. 1, pp.
183–187, 2000.
[10] R. L. Page, W. E. Wilkinson, W. K. Clair, E. A. McCarthy,
and E. L. C. Pritchett, “Asymptomatic arrhythmias in patients
with symptomatic paroxysmal atrial fibrillation andparoxysmal
supraventricular tachycardia,” Circulation, vol. 89, no. 1, pp.
224–227, 1994.
[11] N. Voigt, J. Heijman, Q. Wang et al., “Cellular and molecular
mechanisms of atrial arrhythmogenesis in patients with parox-
ysmal atrial fibrillation,” Circulation, vol. 129, no. 2, pp. 145–156,
2014.
[12] Y.-H. Yeh, R. Wakili, X.-Y. Qi et al., “Calcium-handling abnor-
malities underlying atrial arrhythmogenesis and contractile
dysfunction in dogs with congestive heart failure,” Circulation:
Arrhythmia and Electrophysiology, vol. 1, no. 2, pp. 93–102, 2008.
[13] J.Monigatti-Tenkorang, F. Jousset, P. Pascale et al., “Intermittent
atrial tachycardia promotes repolarization alternans and con-
duction slowing during rapid rates, and increases susceptibility
to atrial fibrillation in a free-behaving sheep model,” Journal
of Cardiovascular Electrophysiology, vol. 25, no. 4, pp. 418–427,
2014.
[14] A. Goette, T. Staack, C. Ro¨cken et al., “Increased expres-
sion of extracellular signal-regulated kinase and angiotensin-
converting enzyme in human atria during atrial fibrillation,”
Journal of the American College of Cardiology, vol. 35, no. 6, pp.
1669–1677, 2000.
[15] R. Zhang, Y. Y. Zhang, X. R. Huang et al., “C-reactive protein
promotes cardiac fibrosis and inflammation in angiotensin II-
induced hypertensive cardiac disease,”Hypertension, vol. 55, no.
4, pp. 953–960, 2010.
[16] Y. Guo, G. Y. H. Lip, and S. Apostolakis, “Inflammation in atrial
fibrillation,” Journal of the American College of Cardiology, vol.
60, no. 22, pp. 2263–2270, 2012.
[17] J. L. Blackshear and J. A. Odell, “Appendage obliteration to
reduce stroke in cardiac surgical patients with atrial fibrillation,”
Annals of Thoracic Surgery, vol. 61, no. 2, pp. 755–759, 1996.
[18] T. Watson, E. Shantsila, and G. Y. Lip, “Mechanisms of throm-
bogenesis in atrial fibrillation: virchow’s triad revisited,” The
Lancet, vol. 373, no. 9658, pp. 155–166, 2009.
[19] T. Sanna, H. C. C. Diener, R. S. Passman et al., “Cryptogenic
stroke and underlying atrial fibrillation,” The New England
Journal of Medicine, vol. 370, no. 26, pp. 2478–2486, 2014.
[20] D. J. Gladstone, M. Spring, P. Dorian et al., “Atrial fibrillation in
patients with cryptogenic stroke,” The New England Journal of
Medicine, vol. 370, no. 26, pp. 2467–2477, 2014.
[21] R. B. Schnabel, L. M. Sullivan, D. Levy et al., “Development of
a risk score for atrial fibrillation (Framingham Heart Study): a
community-based cohort study,”The Lancet, vol. 373, no. 9665,
pp. 739–745, 2009.
[22] A. Mosterd and A. W. Hoes, “Clinical epidemiology of heart
failure,” Heart, vol. 93, no. 9, pp. 1137–1146, 2007.
[23] Biomarkers Definitions Working Group, “Biomarkers and sur-
rogate endpoints: preferred definitions and conceptual frame-
work,” Clinical Pharmacology and Therapeutics, vol. 69, no. 3,
pp. 89–95, 2001.
[24] R. P. Martins, K. Kaur, E. Hwang et al., “Dominant frequency
increase rate predicts transition from paroxysmal to long-term
persistent atrial fibrillation,” Circulation, vol. 129, no. 14, pp.
1472–1482, 2014.
[25] Z. Hijazi, J. Oldgren, U. Andersson et al., “Cardiac biomarkers
are associated with an increased risk of stroke and death in
patients with atrial fibrillation: a randomized evaluation of
long-term anticoagulation therapy (RE-LY) substudy,” Circula-
tion, vol. 125, no. 13, pp. 1605–1616, 2012.
[26] P. E. Dilaveris, E. J. Gialafos, S. K. Sideris et al., “Simple
electrocardiographic markers for the prediction of paroxysmal
idiopathic atrial fibrillation,” The American Heart Journal, vol.
135, no. 5, par 1, pp. 733–738, 1998.
[27] U. Dogan, E. A. Dogan, M. Tekinalp et al., “P-wave dispersion
for predicting paroxysmal atrial fibrillation in acute ischemic
stroke,” International Journal of Medical Sciences, vol. 9, no. 1,
pp. 108–114, 2012.
[28] J. B. Nielsen, C. Graff, A. Pietersen et al., “J-shaped association
between QTc interval duration and the risk of atrial fibrillation:
results from the copenhagen ECG study,” Journal of the Ameri-
can College of Cardiology, vol. 61, no. 25, pp. 2557–2564, 2013.
[29] T. Hoshino, T. Nagao, T. Shiga et al., “Prolonged QTc interval
predicts poststroke paroxysmal atrial fibrillation,” Stroke, vol.
46, pp. 71–76, 2015.
[30] C. Kolb, S. Nu¨rnberger, G. Ndrepepa, B. Zrenner, A. Scho¨mig,
and C. Schmitt, “Modes of initiation of paroxysmal atrial fibril-
lation from analysis of spontaneously occurring episodes using
a 12-lead Holter monitoring system,” The American Journal of
Cardiology, vol. 88, no. 8, pp. 853–857, 2001.
[31] N. Gaillard, S. Deltour, B. Vilotijevic et al., “Detection of
paroxysmal atrial fibrillation with transtelephonic EKG in TIA
or stroke patients,” Neurology, vol. 74, no. 21, pp. 1666–1670,
2010.
BioMed Research International 9
[32] M. Weber-Kru¨ger, K. Gro¨schel, M. Mende et al., “Excessive
supraventricular ectopic activity is indicative of paroxysmal
atrial fibrillation in patients with cerebral ischemia,” PLoS ONE,
vol. 8, no. 6, Article ID e67602, 2013.
[33] D. Wallmann, D. Tu¨ller, K. Wustmann et al., “Frequent atrial
premature beats predict paroxysmal atrial fibrillation in stroke
patients: an opportunity for a new diagnostic strategy,” Stroke,
vol. 38, no. 8, pp. 2292–2294, 2007.
[34] B. Wozakowska-Kapłon, “Effect of sinus rhythm restoration
on plasma brain natriuretic peptide in patients with atrial
fibrillation,”The American Journal of Cardiology, vol. 93, no. 12,
pp. 1555–1558, 2004.
[35] S.-I. Inoue, Y. Murakami, K. Sano, H. Katoh, and T. Shimada,
“Atrium as a source of brain natriuretic polypeptide in patients
with atrial fibrillation,” Journal of Cardiac Failure, vol. 6, no. 2,
pp. 92–96, 2000.
[36] J. Li and L. Wang, “B-type natriuretic peptide levels in patients
with paroxysmal lone atrial fibrillation,” Heart and Vessels, vol.
21, no. 3, pp. 137–140, 2006.
[37] P. T. Ellinor, A. F. Low, K. K. Patton, M. A. Shea, and C.
A. MacRae, “Discordant atrial natriuretic peptide and brain
natriuretic peptide levels in lone atrial fibrillation,” Journal of the
American College of Cardiology, vol. 45, no. 1, pp. 82–86, 2005.
[38] R. Wachter, R. Lahno, B. Haase et al., “Natriuretic peptides for
the detection of paroxysmal atrial fibrillation in patients with
cerebral ischemia—the find-AF study,” PLoS ONE, vol. 7, no. 4,
Article ID e34351, 2012.
[39] K. Sakai, K. Shibazaki, K. Kimura et al., “Brain natriuretic
peptide as a predictor of cardioembolism in acute ischemic
stroke patients: brain natriuretic peptide stroke prospective
study,” European Neurology, vol. 69, no. 4, pp. 246–251, 2013.
[40] A. C. Fonseca, D. Brito, T. Pinho e Melo et al., “N-terminal pro-
brain natriuretic peptide shows diagnostic accuracy for detect-
ing atrial fibrillation in cryptogenic stroke patients,” Interna-
tional Journal of Stroke, vol. 9, no. 4, pp. 419–425, 2014.
[41] I. Beaulieu-Boire, N. Leblanc, L. Berger, and J.-M.M. Boulanger,
“Troponin elevation predicts atrial fibrillation in patients with
stroke or transient ischemic attack,” Journal of Stroke and
Cerebrovascular Diseases, vol. 22, no. 7, pp. 978–983, 2013.
[42] J.-M. M. Bugnicourt, V. Rogez, M.-P. P. Guillaumont, J.-C. C.
Rogez, S. Canaple, and O. Godefroy, “Troponin levels help
predict new-onset atrial fibrillation in ischaemic stroke patients:
a retrospective study,” EuropeanNeurology, vol. 63, no. 1, pp. 24–
28, 2010.
[43] Y. Luan, Y. Guo, S. Li et al., “Interleukin-18 among atrial fib-
rillation patients in the absence of structural heart disease,”
Europace, vol. 12, no. 12, pp. 1713–1718, 2010.
[44] M. K. Chung, D. O. Martin, D. Sprecher et al., “C-reactive pro-
tein elevation in patients with atrial arrhythmias: inflammatory
mechanisms and persistence of atrial fibrillation,” Circulation,
vol. 104, no. 24, pp. 2886–2891, 2001.
[45] M. Rienstra, J. X. Sun, J. W. Magnani et al., “White blood
cell count and risk of incident atrial fibrillation (from the
framingham heart study),”The American Journal of Cardiology,
vol. 109, no. 4, pp. 533–537, 2012.
[46] I. Liuba, H. Ahlmroth, L. Jonasson et al., “Source of inflamma-
tory markers in patients with atrial fibrillation,” Europace, vol.
10, no. 7, pp. 848–853, 2008.
[47] R. R. Huxley, A. Alonso, F. L. Lopez et al., “Type 2 dia-
betes, glucose homeostasis and incident atrial fibrillation: the
Atherosclerosis risk in communities study,” Heart, vol. 98, no.
2, pp. 133–138, 2012.
[48] R. K. Sandhu, D. Conen, U. B. Tedrow et al., “Predisposing
factors associated with development of persistent compared
with paroxysmal atrial fibrillation,” Journal of the American
Heart Association, vol. 3, no. 3, Article ID e000916, 2014.
[49] F. L. Lopez, S. K. Agarwal, R. F. MacLehose et al., “Blood lipid
levels, lipid-lowering medications, and the incidence of atrial
fibrillation : the Atherosclerosis Risk in Communities (ARIC)
study,”Circulation: Arrhythmia and Electrophysiology, vol. 5, no.
1, pp. 155–162, 2012.
[50] B. M. Psaty, T. A. Manolio, L. H. Kuller et al., “Incidence of and
risk factors for atrial fibrillation in older adults,”Circulation, vol.
96, no. 7, pp. 2455–2461, 1997.
[51] F. L. Li-Saw-Hee, A. D. Blann, D. Gurney, and G. Y. H.
Lip, “Plasma von Willebrand factor, fibrinogen and soluble P-
selectin levels in paroxysmal, persistent and permanent atrial
fibrillation: effects of cardioversion and return of left atrial
function,” European Heart Journal, vol. 22, no. 18, pp. 1741–1747,
2001.
[52] G. Y. H. Lip, G. D. O. Lowe, A. Rumley, and F. G. Dunn, “Fib-
rinogen and fibrin D-dimer levels in paroxysmal atrial fibrilla-
tion: evidence for intermediate elevated levels of intravascular
thrombogenesis,” American Heart Journal, vol. 131, no. 4, pp.
724–730, 1996.
[53] E. M. Kallergis, E. G. Manios, E. M. Kanoupakis et al., “Extra-
cellular matrix alterations in patients with paroxysmal and
persistent atrial fibrillation: biochemical assessment of collagen
type-I turnover,” Journal of the American College of Cardiology,
vol. 52, no. 3, pp. 211–215, 2008.
[54] M. Fujita, X. W. Cheng, Y. Inden et al., “Mechanisms with clin-
ical implications for atrial fibrillation-associated remodeling:
cathepsin K expression, regulation, and therapeutic target and
biomarker,” Journal of the American Heart Association, vol. 2,
Article ID e000503, 2013.
[55] C. S. Fox, H. Parise, R. B. D’Agostino et al., “Parental atrial
fibrillation as a risk factor for atrial fibrillation in offspring,”
Journal of the AmericanMedical Association, vol. 291, no. 23, pp.
2851–2855, 2004.
[56] S. A. Lubitz, K. L. Lunetta, H. Lin et al., “Novel genetic mark-
ers associated with atrial fibrillation risk in Europeans and
Japanese,” Journal of the American College of Cardiology, vol. 63,
no. 12, pp. 1200–1210, 2014.
[57] P. T. Ellinor, K. L. Lunetta, C. M. Albert et al., “Meta-analysis
identifies six new susceptibility loci for atrial fibrillation,”
Nature Genetics, vol. 44, no. 6, pp. 670–675, 2012.
[58] B. M. Everett, N. R. Cook, D. Conen, D. I. Chasman, P. M.
Ridker, and C. M. Albert, “Novel genetic markers improve
measures of atrial fibrillation risk prediction,” European Heart
Journal, vol. 34, no. 29, pp. 2243–2251, 2013.
[59] Z. Liu, C. Zhou, Y. Liu et al., “The expression levels of plasma
microRNAs in atrial fibrillation patients,” PLoS ONE, vol. 7, no.
9, Article ID e44906, 2012.
[60] D. D. McManus, K. Tanriverdi, H. Lin et al., “Plasma microR-
NAs are associated with atrial fibrillation and change after
catheter ablation (themiRhythm study),”Heart Rhythm, vol. 12,
no. 1, pp. 3–10, 2015.
[61] J. A. Laukkanen, S. Kurl, J. Era¨nen, M. Huttunen, and J. T.
Salonen, “Left atrium size and the risk of cardiovascular death
in middle-agedmen,”Archives of Internal Medicine, vol. 165, no.
15, pp. 1788–1793, 2005.
[62] S. M. Vaziri, M. G. Larson, E. J. Benjamin, and D.
Levy, “Echocardiographic predictors of nonrheumatic atrial
10 BioMed Research International
fibrillation. The Framingham Heart Study,” Circulation, vol. 89,
no. 2, pp. 724–730, 1994.
[63] R. S. Phang, S. M. Isserman, D. Karia et al., “Echocardiographic
evidence of left atrial abnormality in young patients with
lone paroxysmal atrial fibrillation,” The American Journal of
Cardiology, vol. 94, no. 4, pp. 511–513, 2004.
[64] W. P. Abhayaratna, K. Fatema, M. E. Barnes et al., “Left atrial
reservoir function as a potent marker for first atrial fibrillation
or flutter in persons> or = 65 years of age,”TheAmerican Journal
of Cardiology, vol. 101, no. 11, pp. 1626–1629, 2008.
[65] J. H. Yoon, J. Moon, H. M. Chung et al., “Left atrial function
assessed by doppler echocardiography rather than left atrial
volume predicts recurrence in patients with paroxysmal atrial
fibrillation,”Clinical Cardiology, vol. 36, no. 4, pp. 235–240, 2013.
[66] J. M. Leung, W. H. Bellows, and N. B. Schiller, “Impairment of
left atrial function predicts post-operative atrial fibrillation after
coronary artery bypass graft surgery,” European Heart Journal,
vol. 25, no. 20, pp. 1836–1844, 2004.
[67] G. di Salvo, P. Caso, R. Lo Piccolo et al., “Atrial myocardial
deformation properties predict maintenance of sinus rhythm
after external cardioversion of recent-onset lone atrial fibrilla-
tion: a colorDopplermyocardial imaging and transthoracic and
transesophageal echocardiographic study,” Circulation, vol. 112,
no. 3, pp. 387–395, 2005.
[68] C. Schneider, R. Malisius, K. Krause et al., “Strain rate imaging
for functional quantification of the left atrium: atrial deforma-
tion predicts the maintenance of sinus rhythm after catheter
ablation of atrial fibrillation,” European Heart Journal, vol. 29,
no. 11, pp. 1397–1409, 2008.
[69] M. Zabalgoitia, J. L.Halperin, L. A. Pearce, J. L. Blackshear, R.W.
Asinger, and R. G. Hart, “Transesophageal echocardiographic
correlates of clinical risk of thromboembolism in nonvalvular
atrial fibrillation. Stroke Prevention in Atrial Fibrillation III
Investigators,” Journal of the AmericanCollege of Cardiology, vol.
31, no. 7, pp. 1622–1626, 1998.
[70] Y. Taguchi, S. Takashima, T. Hirai et al., “Significant impairment
of left atrial function in patients with cardioembolic stroke
caused by paroxysmal atrial fibrillation,” Internal Medicine, vol.
49, no. 16, pp. 1727–1732, 2010.
[71] N. Toh, H. Kanzaki, S. Nakatani et al., “Left atrial volume com-
binedwith atrial pump function identifies hypertensive patients
with a history of paroxysmal atrial fibrillation,” Hypertension,
vol. 55, no. 5, pp. 1150–1156, 2010.
[72] R. Stahrenberg, F. Edelmann, B. Haase et al., “Transthoracic
echocardiography to rule out paroxysmal atrial fibrillation as a
cause of stroke or transient ischemic attack,” Stroke, vol. 42, no.
12, pp. 3643–3645, 2011.
[73] A. Selzer and K. E. Cohn, “Natural history of mitral stenosis: a
review,” Circulation, vol. 45, no. 4, pp. 878–890, 1972.
[74] F. Grigioni, J.-F. Avierinos, L. H. Ling et al., “Atrial fibrillation
complicating the course of degenerative mitral regurgitation:
determinants and long-term outcome,” Journal of the American
College of Cardiology, vol. 40, no. 1, pp. 84–92, 2002.
[75] Z. M. Gertz, A. Raina, L. Saghy et al., “Evidence of atrial
functional mitral regurgitation due to atrial fibrillation: reversal
with arrhythmia control,” Journal of the American College of
Cardiology, vol. 58, no. 14, pp. 1474–1481, 2011.
[76] J. Yi, D. Lee, E. J. Cho, H. Jeon, H. Jung, and H. Youn, “Doppler-
derived left ventricular negative dP/dt as a predictor of atrial fib-
rillation or ischamic stroke in patients with degenerative mitral
regurgitation and normal ejection fraction,” Echocardiography,
vol. 31, no. 3, pp. 285–292, 2014.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
